Company Profile
Nurix Therapeutics Stock Price, News & Analysis
- Ticker:
- NRIX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
25.22 USD (+0.40%)
Close
Last updated: August 6, 2026
1.69B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, NRIX closed up 0.40% at $25.22. No new same-company headline was identified in the current news window.
Company overview
Targeted Protein Degradation
Nurix Therapeutics develops medicines that use the cell’s ubiquitin-proteasome system to remove disease-causing proteins. Its portfolio includes wholly owned degraders and programs partnered with large pharmaceutical companies.
Bexobrutideg
Bexobrutideg is an oral BTK degrader being advanced as a potential best-in-class therapy for relapsed or refractory chronic lymphocytic leukemia. Unlike an inhibitor, it is designed to eliminate both catalytic and scaffolding functions of the BTK protein.
Registrational CLL Program
DAYBreak CLL-201 is a pivotal single-arm Phase 2 trial intended to support accelerated approval. DAYBreak CLL-306 is a planned randomized Phase 3 confirmatory trial comparing bexobrutideg with pirtobrutinib after prior BTK inhibitor therapy.
Immunology Expansion
Nurix is evaluating a new bexobrutideg tablet formulation and healthy-volunteer data to support development in inflammatory and autoimmune diseases. Removing BTK may offer broader pathway suppression than conventional kinase inhibition.
Partnered Degrader Pipeline
Partnered programs include an IRAK4 degrader in Phase 1 development and a STAT6 degrader in IND-enabling studies. Collaborations with Gilead, Sanofi and Pfizer extend the platform across multiple targets and therapeutic areas.
Future catalysts
Initiation of the Phase 3 DAYBreak CLL-306 trial planned by mid-2026.
Updated bexobrutideg clinical data at medical meetings throughout 2026.
IND submission for bexobrutideg in immunology and inflammation targeted in 2026.
Recent news
- 01
- 02
- 03
- 04
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Source: Nurix Therapeutics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Nurix Therapeutics (NRIX)?
Nurix Therapeutics (NRIX) most recently closed at 25.22 USD, a +0.40% move versus the previous session.
What is the market cap of Nurix Therapeutics (NRIX)?
Nurix Therapeutics currently has a market capitalization of 1.69B USD on BioPharmSignal.
What does Nurix Therapeutics do?
Targeted Protein Degradation Nurix Therapeutics develops medicines that use the cell’s ubiquitin-proteasome system to remove disease-causing proteins. Its portfolio includes wholly owned degraders and programs partnered with large pharmaceutical companies. Bexobrutideg Bexobrutideg is an oral BTK degrader being advanced as a potential best-in-class therapy...
On which exchange is NRIX stock listed?
Nurix Therapeutics (NRIX) is associated with NASDAQ, United States, Biopharma.
What is CLL-201?
Registrational CLL Program DAYBreak CLL-201 is a pivotal single-arm Phase 2 trial intended to support accelerated approval.
Which conditions is Nurix Therapeutics targeting with CLL-201?
Nurix Therapeutics is associated with immunology, inflammatory disease based on its company overview and current catalyst commentary.
How does Nurix Therapeutics describe recent progress with CLL-201?
Initiation of the Phase 3 DAYBreak CLL-306 trial planned by mid-2026. Updated bexobrutideg clinical data at medical meetings throughout 2026. IND submission for bexobrutideg in immunology and inflammation targeted in 2026.
What is CLL-306?
DAYBreak CLL-306 is a planned randomized Phase 3 confirmatory trial comparing bexobrutideg with pirtobrutinib after prior BTK inhibitor therapy.